Shareholders Equity: The sum of preferred and common equity items.
Celldex Therapeutics, Inc. (CLDX) had Shareholders Equity of $747.00M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$7.02M |
|
$-157.86M |
|
-- |
|
$7.02M |
|
$202.10M |
|
$-195.08M |
|
$37.22M |
|
$-157.86M |
|
$-157.86M |
|
$-157.86M |
|
$-157.86M |
|
$-157.86M |
|
$-157.86M |
|
$-195.08M |
|
$-207.65M |
|
64.39M |
|
64.39M |
|
$-2.45 |
|
$-2.45 |
|
| Balance Sheet Financials | |
$747.16M |
|
$4.35M |
|
$45.18M |
|
$792.34M |
|
$39.50M |
|
-- |
|
$5.83M |
|
$45.34M |
|
$747.01M |
|
$719.82M |
|
|
Shareholders Equity |
$747.00M |
66.38M |
|
| Cash Flow Statement Financials | |
$-157.78M |
|
$-290.13M |
|
$441.45M |
|
$34.81M |
|
$28.36M |
|
$-6.46M |
|
$34.24M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
18.91 |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
100.00% |
|
-2778.89% |
|
-2778.89% |
|
-2957.98% |
|
-2248.76% |
|
-2248.76% |
|
$-159.70M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
10.03 |
|
36.40 |
|
-21.13% |
|
-21.93% |
|
-19.92% |
|
-21.13% |
|
$11.25 |
|
$-2.48 |
|
$-2.45 |
|